Kang Sun

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Claire Harrison, Alessandro M. Vannucchi, Haifa Kathrin Al‐Ali et al. · Leukemia · 2016 · 509 citations · Full text

Medicine, Hematology, Pharmacology +13

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · Journal of Hematology & Oncology · 2017 · 427 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

Kim Papp, Jacek C. Szepietowski, Leon Kircik et al. · Journal of the American Academy of Dermatology · 2021 · 297 citations

Medicine, Dermatology, Pharmacotherapy +16

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

Xi-Chun Hu, Jian Zhang, Bing-He Xu et al. · The Lancet Oncology · 2015 · 285 citations

Medicine, Oncology, Pharmacology +15

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

David Rosmarin, Thierry Passeron, Amit G. Pandya et al. · New England Journal of Medicine · 2022 · 266 citations

Medicine, Dermatology, Pharmacology +15